SMAD7 and cancer: In the overall analysis, we detected a significant association between SMAD7 rs12953717 polymorphism and cancer susceptibility under homozygote comparison (OR = 1.23, 95%CI = 1.10–1.38, P<0.01; Figure S2), heterozygote comparison (OR = 1.12, 95%CI = 1.02–1.22, P = 0.02; Figure S3), recessive model (OR = 1.17, 95%CI = 1.07–1.29, P<0.01; Figure S4), dominant model (OR = 1.15, 95%CI = 1.06–1.25, P<0.01; Figure S5), and allelic model (OR = 1.12, 95%CI = 1.06–1.18, P<0.01; Figure S6).